Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEFLOQUINE HYDROCHLORIDE vs ARALEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mefloquine is a quinoline antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown but is thought to involve forming toxic heme complexes or inhibiting heme polymerase, leading to parasite death.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.
Treatment of mild to moderate acute malaria caused by Plasmodium falciparum (including chloroquine-resistant strains) and Plasmodium vivax,Prophylaxis of malaria in travelers to endemic regions
Treatment of uncomplicated malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum,Prophylaxis of malaria in areas with chloroquine-sensitive P. falciparum,Treatment of extraintestinal amebiasis (as amebicide) and giardiasis (off-label),Disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and lupus erythematosus (off-label)
250 mg (1 tablet) orally once weekly for prophylaxis; 1250 mg (5 tablets) as a single oral dose for treatment of uncomplicated malaria.
Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.
~2-4 weeks (terminal half-life); clinical context: long half-life allows weekly dosing for prophylaxis, but accumulation can occur with repeated doses.
Terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) due to extensive tissue binding; clinical context: prolonged half-life allows weekly dosing for malaria prophylaxis.
Primarily metabolized by the liver via cytochrome P450 enzymes, including CYP3A4. Forms one main metabolite, 4-carboxymefloquine, which is inactive.
Chloroquine is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, to active metabolites such as desethylchloroquine. It has a long elimination half-life of approximately 1-2 months.
~83% (fecal/biliary), ~9% (renal unchanged), ~2.5% (renal as metabolite).
Primarily renal (approximately 70% as unchanged drug); minor biliary/fecal (about 10-20%).
~98% bound to albumin and alpha-1-acid glycoprotein (AAG).
Approximately 50-60% bound; primarily to albumin and alpha-1-acid glycoprotein.
~13-29 L/kg (large Vd, extensive tissue distribution, including RBCs).
Very large, 100-200 L/kg; extensive tissue distribution (liver, spleen, kidney, lungs, melanin-containing tissues).
Oral: ~85-90% (relative to oral solution).
Oral: 80-90%.
No adjustment required for mild to moderate renal impairment (Cr Cl >30 m L/min). For severe renal impairment (Cr Cl <30 m L/min) or hemodialysis, use with caution and monitor for adverse effects; consider alternative antimalarial.
For malaria prophylaxis: No adjustment necessary. For treatment: If Cr Cl < 10 m L/min, reduce dose by 50%.
Contraindicated in patients with active hepatitis or elevated liver enzymes. For Child-Pugh class A, no adjustment; for class B or C, avoid use due to risk of hepatic toxicity.
No formal guidelines; use caution in severe hepatic impairment due to potential accumulation. Consider dose reduction in Child-Pugh class C.
Prophylaxis: 5 mg/kg (max 250 mg) orally once weekly. Treatment: 20-25 mg/kg (max 1250 mg) as a single oral dose. Use only in children >5 kg.
Prophylaxis: 5 mg/kg base (8.3 mg/kg salt) orally once weekly, max 300 mg base. Treatment: 10 mg/kg base (16.7 mg/kg salt) orally initially, followed by 5 mg/kg base at 6, 24, and 48 hours, max 600 mg base on day 1.
Use standard adult dosing but monitor closely for neuropsychiatric adverse effects (e.g., dizziness, confusion). Consider lower initial dose (e.g., 250 mg weekly) and titrate based on tolerance.
No specific adjustments; consider age-related renal impairment and potential increased risk of QT prolongation. Monitor for cardiac effects.
Mefloquine may cause neuropsychiatric adverse reactions including dizziness, vertigo, tinnitus, and more severe effects such as psychosis, seizures, and suicidal ideation. Use with caution and consider alternative prophylaxis in patients with psychiatric or seizure disorders.
Retinopathy: Irreversible retinal damage including retinopathy and visual disturbances; risk increases with cumulative dose and duration of use; contraindicated in patients with pre-existing retinopathy; baseline and periodic ophthalmologic exams required.
Neuropsychiatric effects: can occur weeks to months after discontinuation; avoid in patients with active depression, generalized anxiety disorder, psychosis, or schizophrenia,Hepatic impairment: use caution; may exacerbate liver disease,Ocular effects: rare visual disturbances including retinopathy,Cardiac effects: may cause QT prolongation; avoid with other QT-prolonging drugs,Seizures: use caution in patients with history of seizures
Retinopathy risk with prolonged use; cardiac effects including conduction disorders (e.g., QT prolongation) and cardiomyopathy; exacerbation of psoriasis and porphyria; neuropsychiatric effects (e.g., psychosis, seizures); hematologic toxicity (eg, agranulocytosis, aplastic anemia); hypoglycemia; myopathy; ototoxicity. Use with caution in hepatic or renal impairment, G6PD deficiency, and pregnancy (benefit vs risk).
History of hypersensitivity to mefloquine or related compounds (e.g., quinine, quinidine),Active psychiatric conditions such as depression, generalized anxiety disorder, psychosis, schizophrenia, or suicidal tendencies,History of seizures or a family history of epilepsy,Use with halofantrine or other drugs that prolong QT interval
Hypersensitivity to chloroquine or 4-aminoquinolines; pre-existing retinopathy of any etiology; concurrent use with other agents causing retinal toxicity (e.g., hydroxychloroquine, tamoxifen); porphyria; psoriasis (relative, may exacerbate); neuromyopathy (relative); severe hepatic or renal impairment (relative).
Grapefruit and grapefruit juice may increase mefloquine concentrations; avoid concurrent use. Take with food to reduce nausea and vomiting. No other significant food interactions reported.
Avoid grapefruit juice as it may increase chloroquine levels. No other significant food interactions.
First trimester: Avoid due to potential teratogenicity (animal data show skeletal and vascular anomalies; limited human data suggest possible increased risk of miscarriage and malformations). Second and third trimesters: Use only if benefit outweighs risk; no clear evidence of major human teratogenicity in later trimesters.
Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third trimesters: Risk of sensorineural hearing loss, vestibular damage, and retinal toxicity in the fetus if used for prolonged periods or at high doses; accumulation in fetal ocular tissues reported.
Mefloquine is excreted into breast milk in small amounts (M/P ratio approximately 0.33-0.47). Amount is insufficient to cause adverse effects in term infants; however, caution in preterm or ill infants. Consider alternative antimalarials if infant has G6PD deficiency.
Excreted in breast milk in small amounts (M/P ratio approximately 0.44). American Academy of Pediatrics considers compatible with breastfeeding, but caution is advised in infants with glucose-6-phosphate dehydrogenase deficiency or hemolytic disease. Monitor infant for rash, retinal changes, and hemolysis.
No dose adjustment required for prophylaxis; for treatment, standard doses may be used but monitor for increased volume of distribution and decreased peak concentrations; consider extended interval or increased dose if efficacy concerns arise, though not routinely recommended.
No specific dose adjustment recommended for pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma concentrations) may require therapeutic drug monitoring, but empirical dose adjustments are not established. Use lowest effective dose and shortest duration.
Mefloquine is contraindicated in patients with active depression, generalized anxiety disorder, psychosis, or a history of convulsions. Due to long half-life (18-22 days), neuropsychiatric effects may persist or appear weeks after discontinuation. Use with caution in patients with hepatic impairment; monitor liver function. Cardiotoxicity: avoid use with QT-prolonging drugs; ECG monitoring recommended if concomitant use inevitable. Efficacy against multidrug-resistant P. falciparum is strain-dependent; consider regional resistance patterns. For malaria prophylaxis, start 2-3 weeks before travel to assess tolerability.
Chloroquine (Aralen) can cause retinal toxicity; cumulative dose should not exceed 200g. Use with caution in G6PD deficiency. Can prolong QTc interval; avoid with other QTc-prolonging drugs.
Take exactly as prescribed; do not stop early even if feeling better.,Report any psychiatric symptoms (anxiety, depression, unusual dreams, confusion) immediately.,Avoid alcohol; may increase risk of liver toxicity and CNS effects.,Take with food and a full glass of water to reduce gastrointestinal upset.,Use effective contraception during therapy and for 3 months after last dose; may cause fetal harm.,Do not drive or operate machinery if dizziness, vertigo, or visual disturbances occur.,Complete full course for malaria treatment; for prophylaxis, continue for 4 weeks after leaving endemic area.
Take with food to reduce gastrointestinal upset.,Do not exceed prescribed dose; overdose can be fatal.,Report any vision changes immediately; regular eye exams are required.,Avoid alcohol as it may increase risk of liver toxicity.,Inform your doctor if you have a history of heart rhythm problems.
"Mefloquine reduces the anticholinergic effects of biperiden by inducing CYP3A4, increasing biperiden metabolism, leading to reduced efficacy. This may worsen Parkinsonian symptoms or extrapyramidal side effects in patients using biperiden. Clinically, patients may experience diminished control of drug-induced movement disorders."
"Moxifloxacin, a fluoroquinolone antibiotic, and mefloquine, an antimalarial agent, both prolong the QT interval by inhibiting cardiac potassium channels (specifically hERG channels). When coadministered, there is an additive effect on QTc prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias. This interaction is particularly dangerous in patients with preexisting cardiac conditions, electrolyte imbalances, or bradycardia."
"The co-administration of mefloquine, a quinoline antimalarial known to lower seizure threshold, may antagonize the anticonvulsant effects of progabide, a GABA receptor agonist. This interaction can lead to reduced efficacy of progabide, potentially precipitating breakthrough seizures in patients with epilepsy. Clinically, this may result in inadequate seizure control and necessitate dosage adjustments or alternative therapies."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEFLOQUINE HYDROCHLORIDE vs ARALEN, answered by our medical review team.
MEFLOQUINE HYDROCHLORIDE is a Antimalarial that works by Mefloquine is a quinoline antimalarial agent that acts as a blood schizontocide. Its exact mechanism is unknown but is thought to involve forming toxic heme complexes or inhibiting heme polymerase, leading to parasite death.. ARALEN is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEFLOQUINE HYDROCHLORIDE and ARALEN depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEFLOQUINE HYDROCHLORIDE is: 250 mg (1 tablet) orally once weekly for prophylaxis; 1250 mg (5 tablets) as a single oral dose for treatment of uncomplicated malaria.. The standard adult dose of ARALEN is: Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEFLOQUINE HYDROCHLORIDE and ARALEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEFLOQUINE HYDROCHLORIDE is classified as Category A/B. First trimester: Avoid due to potential teratogenicity (animal data show skeletal and vascular anomalies; limited human data suggest possible increased risk of miscarriage and malf. ARALEN is classified as Category C. Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.